X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Bill Chin, M.D.

Bill Chin, M.D. Dr. Bill Chin is the chief medical officer of PhRMA and leads the Scientific & Regulatory Advocacy department as executive vice president. A physician, an endocrinologist and an academic at heart, Dr. Chin envisions establishing PhRMA as the premiere convener in advancing drug discovery and development, regulatory sciences and collaborative partnerships.

Recent Posts

Mental health in the New Era of Medicine

By Bill Chin, M.D.  |    April 18, 2017
Research and development of innovative medicines to promote mental health are a priority for America’s biopharmaceutical research companies. With more than 130 medicines in development for mental...   Read More

Exploring the new era of medicine

By Bill Chin, M.D.  |    February 21, 2017
We are in a new era of medicine where innovations are transforming our ability to attack the cause of disease, not just the symptoms. Where treatment decisions are increasingly focused on the...   Read More

Reflecting on terrific progress in treating diabetes

By Bill Chin, M.D.  |    November 17, 2016
There is no doubt that diabetes is a complex disease to diagnose and treat. That’s something I’ve seen firsthand as an endocrinologist. Over the years, I treated a number of patients that had a...   Read More

What are REMS? These extra steps are helping protect patient health

By Bill Chin, M.D.  |    October 6, 2016
As a physician and chief medical officer at PhRMA, I know how important it is to ensure that patients have access to safe, innovative medicines to help them live longer, healthier lives. But...   Read More

Our continued commitment to combating Ebola

By Bill Chin, M.D.  |    October 15, 2015
Since March of 2014, there have been more than 28,000 cases of Ebola in West Africa, with more than 11,000 deaths, according to the World Health Organization (WHO).  From the beginning of the...   Read More

The War on Alzheimer’s: Progress and Challenges of Biopharmaceutical Research

By Bill Chin, M.D.  |    July 15, 2015
Alzheimer’s disease steals memories, relationships and independence. It is a ruthless, devastating disease ravaging more than 5 million people in the United States alone, and is the sixth-leading...   Read More

Newly Implemented Expanded Access Principles Support Commitment to Patients

By Bill Chin, M.D.  |    June 3, 2015
Biopharmaceutical companies are committed to helping patients gain access to the best possible care, and its researchers are constantly looking for ways to provide more therapeutic options for...   Read More

Biopharmaceutical Sector Leads the Way in Clinical Trial Data Sharing

By Bill Chin, M.D.  |    March 15, 2015
Effective and responsible sharing of clinical trial data continues to expand scientific discourse and discovery, as we have chronicled here on the Catalyst. Through the PhRMA-EFPIA Principles for...   Read More

India—Seizing the Opportunity

By Bill Chin, M.D.  |    February 19, 2015
I am excited to be in India this week to discuss the scientific landscape of pharmaceutical research and development. Everywhere I go I see so much potential for India to become a leader in the...   Read More

PhRMA Salutes Outgoing FDA Commissioner’s Leadership, Looks Forward to Continued Collaboration

By Bill Chin, M.D.  |    February 10, 2015
Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month.   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates